Published on : Aug 11, 2017
Albany, New York, August 11, 2017: Recent advances in molecular biology resulted in significant improvement in the understanding of the pathogenesis of thyroid carcinoma. In recent years, several targeted therapeutics advances are active in the research field for the treatment of a rare form of thyroid cancer, which is Medullary Thyroid Cancer. Market Research Hub (MRH) has recently announced the addition of a new study, titled “Medullary Thyroid Cancer-Pipeline Insight, 2017” to its massive collection of research reports. This study provides a comprehensive understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products.
In the first part, the study presents a snapshot of the pipeline development for the Medullary Thyroid Cancer. Medullary carcinoma of the thyroid is cancer of the thyroid gland that starts in cells which release a hormone called calcitonin. These cells are called "C" cells. The thyroid gland is located in the front of your lower neck. Medullary thyroid cancer is the third most common type of thyroid cancer. The key risk factor for MTC is genetics. Nearly 20% of cases of medullary thyroid cancer is linked with one of three familial syndromes known as multiple endocrine neoplasia. There are 2 forms of MTC, which include sporadic MTC and Inherited MTC. The research also studied that the cause of medullary carcinoma of the thyroid (MTC) is unknown. MTC is very rare. It can occur in children and adults.
Moreover, the research examines that standard treatments in some cases of advanced differentiated thyroid cancer and medullary thyroid cancer have been unsatisfactory and therefore new therapies are necessary. In the past decade, multiple clinical trials have been carried out for the development of new treatments that target biological substrates. This paper will focus on current clinical trials and recent therapies on specific target involved in Medullary Thyroid Cancer. At present, there are several treatment options for medullary thyroid cancer, including external beam radiation and a thyroidectomy. Although surgery remains the standard treatment for medullary thyroid carcinoma (MTC), various medications have entered clinical trials.
Further, the research outlays comprehensive information on the medullary thyroid cancer targeted therapeutics development, completed with analysis by stage of development, indication, mechanism of action (MoA), route of administration (RoA), molecule type and development by companies. Moving further, the drug profiles, their mechanism of action, and their research and development progress have also been encapsulated in this study.
The report is a detailed analysis that is proofed with primary, secondary research and validated by an expert panel. The report also comprises of tables and figures that provide the pictorial representation of the details described in the provided researched report and thus assist in easy analysis.
Request a Sample with TOC in a PDF format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265409
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org